Afuco™ Anti-KDR ADCC Therapeutic Antibody (Ramucirumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to VEGF Receptor 2. Ramucirumab (IMC-1121B) is a fully human monoclonal antibody (IgG1) for the treatment of solid tumors. It is directed against the vascular endothelial growth factor receptor 2 (VEGFR2). By binding to VEGFR2 it works as a receptor antagonist blocking the binding of vascular endothelial growth factor (VEGF) to VEGFR2. VEGFR2 is known to mediate the majority of the downstream effects of VEGF in angiogenesis.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-079 |
| Pricing | Inquiry |
| Host | Human |
| Target | KDR |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | IP, IF, FuncS, FC, Neut, ELISA |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |